Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telithromycin.

Karen M Spiers1, Marcus J Zervos

  • 1Division of Infectious Diseases, William Beaumont Hospital, Royal Oak, MI 48073, USA. kmspiers@aol.com

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infections" [International Journal of Infectious Diseases, 61 (2017) 3-6].

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same author

Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey.

Infectious diseases and therapy·2024
Same author

Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Aminopenicillins vs non-aminopenicillins for treatment of enterococcal lower urinary tract infections.

International journal of antimicrobial agents·2023
Same author

Pandemic response gaps: Infection prevention and control lessons learned during coronavirus disease 2019 (COVID-19) outbreaks in skilled nursing facilities in Detroit, Michigan.

Infection control and hospital epidemiology·2022
Same author

PROPHETIC EU: Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive Care Unit in European and United States Cohorts.

Open forum infectious diseases·2022
Same journal

Study of prescription-indication of antivirals for herpesviruses in a Colombian population: a cross-sectional study.

Expert review of anti-infective therapy·2026
Same journal

Effectiveness and safety of eravacycline-based regimens for resistant <i>Acinetobacter baumannii</i> infections: a systematic review and meta-analysis.

Expert review of anti-infective therapy·2026
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
Same journal

The endocarditis team: a review.

Expert review of anti-infective therapy·2026
Same journal

Synergistic antifungal effects and potential mode of action of crisaborole combined with azoles against drug-resistant <i>Candida albicans</i>.

Expert review of anti-infective therapy·2026
See all related articles

Telithromycin is a novel antibiotic effective for respiratory infections, showing high activity against resistant pathogens. It offers convenient dosing and comparable efficacy to other treatments with manageable side effects.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Increasing resistance to penicillin and macrolides among respiratory pathogens necessitates new therapeutic options.
  • Telithromycin, a novel ketolide antibiotic, was developed to address these challenges.

Purpose of the Study:

  • To evaluate the efficacy and safety of telithromycin for treating upper and lower respiratory tract infections.
  • To assess telithromycin's activity against pathogens with reduced susceptibility to common antibiotics.

Main Methods:

  • Clinical trials comparing telithromycin to standard treatments for respiratory infections.
  • In vitro studies assessing telithromycin's spectrum of activity against respiratory pathogens.

Main Results:

Related Experiment Videos

  • Telithromycin demonstrated efficacy equal or superior to comparator agents.
  • It exhibits broad in vitro activity against common respiratory pathogens, including resistant strains.
  • Rapid penetration into bronchopulmonary tissue and once-daily oral dosing enhance patient compliance.

Conclusions:

  • Telithromycin is an effective first-line treatment for mild to moderate respiratory infections in adults.
  • Its activity against resistant pathogens and favorable pharmacokinetic profile make it a valuable therapeutic option.